Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro

被引:124
作者
Swart, PJ
Kuipers, ME
Smit, C
Pauwels, R
DeBethune, MP
DeClercq, E
Meijer, DKF
Huisman, JG
机构
[1] KATHOLIEKE UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM
[2] NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT DEV RES,1066 CX AMSTERDAM,NETHERLANDS
关键词
D O I
10.1089/aid.1996.12.769
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A number of native and modified milk proteins from bovine or human sources were analyzed for their inhibitory effects on human immunodeficiency virus type 1 (HIV-1) and HIV-2 in vitro in an MT4 cell test system, The proteins investigated were lactoferrin, alpha-lactalbumin, beta-lactoglobulin A, and beta-lactoglobulin B. By acylation of the amino function of the lysine residues in the proteins, using anhydrides of succinic acid or cis-aconitic acid, protein derivatives were obtained that all showed a strong antiviral activity against human immunodeficiency virus type 1 and/or 2. The in vitro IC50 values of the aconitylated proteins were in the concentration range of 0.3 to 3 nM. Succinylation or aconitylation of alpha-lactalbumin and beta-lactoglobulin A/B also produced strong anti-HIV-2 activity with IC50 values on the order 500 to 3000 nM. All compounds showed virtually no cytotoxicity at the concentration used. Peptide-scanning studies indicated that the native lactoferrin as well as the charged modified proteins strongly bind to the V3 loop of the gp120 envelope protein, with K-d values in the same concentration range as the above-mentioned IC50. Therefore, shielding of this domain, resulting in inhibition of virus-cell fusion and entry of the virus into MT4 cells, may be the likely underlying mechanism of antiviral action.
引用
收藏
页码:769 / 775
页数:7
相关论文
共 32 条
[11]   ANTIVIRAL EFFECTS OF PLASMA AND MILK-PROTEINS - LACTOFERRIN SHOWS POTENT ACTIVITY AGAINST BOTH HUMAN-IMMUNODEFICIENCY-VIRUS AND HUMAN CYTOMEGALOVIRUS REPLICATION IN-VITRO [J].
HARMSEN, MC ;
SWART, PJ ;
DEBETHUNE, MP ;
PAUWELS, R ;
DECLERCQ, E ;
THE, TH ;
MEIJER, DKF .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02) :380-388
[12]   GLYCOSAMINOGLYCANS - MOLECULAR-PROPERTIES, PROTEIN INTERACTIONS, AND ROLE IN PHYSIOLOGICAL PROCESSES [J].
JACKSON, RL ;
BUSCH, SJ ;
CARDIN, AD .
PHYSIOLOGICAL REVIEWS, 1991, 71 (02) :481-539
[13]   PHARMACOKINETIC ANALYSIS AND CELLULAR-DISTRIBUTION OF THE ANTI-HIV COMPOUND SUCCINYLATED HUMAN SERUM-ALBUMIN (SUC-HSA) IN-VIVO AND IN THE ISOLATED-PERFUSED RAT-LIVER [J].
JANSEN, RW ;
OLINGA, P ;
HARMS, G ;
MEIJER, DKF .
PHARMACEUTICAL RESEARCH, 1993, 10 (11) :1611-1614
[14]  
JANSEN RW, 1991, MOL PHARMACOL, V39, P818
[15]  
JANSEN RW, 1993, MOL PHARMACOL, V44, P1003
[16]  
KAMIMOTO Y, 1994, LIVER, V14, P141
[17]  
KUIPERS ME, 1995, IN PRESS J ACQUIR IM
[18]   LIPOSOMAL AMPHOTERICIN-B FOR LEISHMANIASIS TREATMENT OF AIDS PATIENTS UNRESPONSIVE TO ANTIMONIUM COMPOUNDS [J].
LAZANAS, MC ;
TSEKES, GA ;
PAPANDREOU, S ;
HARHALAKIS, N ;
SCANDALI, A ;
NIKIFORAKIS, E ;
SAROGLOU, G .
AIDS, 1993, 7 (07) :1018-1019
[19]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[20]  
MATTHEWS THJ, 1976, LANCET, V25, P1378